Utility of Using the Montreal Cognitive Assessment (MoCA) As a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2018 Mar 7

PMID 29508103

Citations 14

Authors

Trena Mukherjee

Rishanantini Sakthivel

Ho Yen Fong

Megan McStea

Meng Li Chong

Sharifah Faridah Omar

Ai Vyrn Chin

Shahrul Kamaruzzaman

Adeeba Kamarulzaman

Reena Rajasuriar

Lucette A Cysique

Affiliations

Soon will be listed here.

Abstract

This study determines the optimal cut-off scores for the Montreal Cognitive Assessment (MoCA) to detect HIV-associated neurocognitive disorders (HAND) in a multi-ethnic Malaysian HIV-positive cohort by developing demographically corrected normative standards among 283 HIV-negative community-based controls with overlapping demographic characteristics. The norms (corrected for age, sex, education, ethnicity) were applied to 342 HIV-positive virally suppressed individuals on cART. Impairment rates were classified using the Global Deficit Score (GDS ≥ .5) method. The MoCA was also scored according to the recommended cut-off of ≤ 26, and functional decline was applied to both impairment definitions to classify HAND per the Frascati criteria. The ≤ 26 cut-off considerably overestimated cognitive impairment in both samples (59.4% HIV-negative; 69.3% HIV-positive). In contrast, corrected scores yielded impairment rates consistent with what has been reported internationally in virally suppressed cohorts (23.4% with 83.3% mild impairment, 16.7% moderate impairment). A supplemental file allowing the computation of corrected MoCA scores and impairment status is included.

Citing Articles

Assessing intrinsic capacity for person-centred HIV care: a cross-sectional study in ageing populations in Malaysia and Hong Kong.

Rajasuriar R, Hisham S, Lim J, Cheong J, Ho W, Yap S J Int AIDS Soc. 2024; 28(1):e26404.

PMID: 39724272 PMC: 11670474. DOI: 10.1002/jia2.26404.

Cognitive Assessment of Young Adults Before and After Initiation of Combination Antiretroviral Therapy.

Gul O, Gunduz A, Sevgi D, Demirbas N, Uzun N, Dokmetas I Infect Dis Clin Microbiol. 2024; 4(3):163-171.

PMID: 38633390 PMC: 10986713. DOI: 10.36519/idcm.2022.154.

Psychosocial risk factors and cognitive decline in people living with HIV: results from the Malaysian HIV and aging (MHIVA) study.

Neelamegam M, Ahmad A, Chong M, Wong P, Zulhaimi N, Cysique L AIDS Care. 2023; 36(8):1041-1049.

PMID: 37666210 PMC: 10909927. DOI: 10.1080/09540121.2023.2254543.

Neuropsychological Test Norms for the Assessment of HIV-Associated Neurocognitive Impairment Among South African Adults.

Deist M, Suliman S, Kidd M, Franklin D, Cherner M, Heaton R AIDS Behav. 2023; 27(9):3080-3097.

PMID: 36918465 PMC: 10386947. DOI: 10.1007/s10461-023-04029-9.

Frailty and Aging in HIV- Status Post 13 Years of National Awareness.

Eke U, Mohanty K, Gruber-Baldini A, Ryan A J Frailty Aging. 2023; 12(1):49-58.

PMID: 36629084 PMC: 10082638. DOI: 10.14283/jfa.2022.45.

References

Carey C, Woods S, Gonzalez R, Conover E, Marcotte T, Grant I . Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004; 26(3):307-19. DOI: 10.1080/13803390490510031. View

Kamminga J, Cysique L, Lu G, Batchelor J, Brew B . Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide. Curr HIV/AIDS Rep. 2013; 10(4):342-55. PMC: 3851699. DOI: 10.1007/s11904-013-0176-6. View

Hoops S, Nazem S, Siderowf A, Duda J, Xie S, Stern M . Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009; 73(21):1738-45. PMC: 2788810. DOI: 10.1212/WNL.0b013e3181c34b47. View

Blackstone K, Moore D, Franklin D, Clifford D, Collier A, Marra C . Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012; 26(6):894-908. PMC: 3848322. DOI: 10.1080/13854046.2012.694479. View

Morgan E, Woods S, Scott J, Childers M, Beck J, Ellis R . Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2007; 30(1):83-90. PMC: 3659773. DOI: 10.1080/13803390701233865. View

Ku N, Lee Y, Ahn J, Song J, Kim M, Kim S . HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project. HIV Med. 2014; 15(8):470-7. PMC: 4140963. DOI: 10.1111/hiv.12137. View

Gates T, Cysique L . The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. CNS Drugs. 2016; 30(1):53-69. PMC: 4733144. DOI: 10.1007/s40263-015-0302-7. View

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

Heaton R, Clifford D, Franklin Jr D, Woods S, Ake C, Vaida F . HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75(23):2087-96. PMC: 2995535. DOI: 10.1212/WNL.0b013e318200d727. View

10.

Chan L, Kandiah N, Chua A . HIV-associated neurocognitive disorders (HAND) in a South Asian population - contextual application of the 2007 criteria. BMJ Open. 2012; 2(1):e000662. PMC: 3282293. DOI: 10.1136/bmjopen-2011-000662. View

11.

Ene L, Franklin D, Burlacu R, Luca A, Blaglosov A, Ellis R . Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood. J Neurovirol. 2014; 20(5):496-504. PMC: 4324616. DOI: 10.1007/s13365-014-0275-1. View

12.

Graf C . The Lawton Instrumental Activities of Daily Living (IADL) Scale. Medsurg Nurs. 2009; 18(5):315-6. View

13.

Tey N, Siraj S, Kamaruzzaman S, Chin A, Tan M, Sinnappan G . Aging in Multi-ethnic Malaysia. Gerontologist. 2015; 56(4):603-9. DOI: 10.1093/geront/gnv153. View

14.

Sanmarti M, Ibanez L, Huertas S, Badenes D, Dalmau D, Slevin M . HIV-associated neurocognitive disorders. J Mol Psychiatry. 2015; 2(1):2. PMC: 4416263. DOI: 10.1186/2049-9256-2-2. View

15.

Heaton R, Marcotte T, Rivera Mindt M, Sadek J, Moore D, Bentley H . The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004; 10(3):317-31. DOI: 10.1017/S1355617704102130. View

16.

Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U . Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010; 16(1):76-82. DOI: 10.3109/13550280903493914. View

17.

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori M, Visco-Comandini U . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007; 45(2):174-82. DOI: 10.1097/QAI.0b013e318042e1ee. View

18.

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

19.

Copersino M, Fals-Stewart W, Fitzmaurice G, Schretlen D, Sokoloff J, Weiss R . Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol. 2009; 17(5):337-44. PMC: 3144764. DOI: 10.1037/a0017260. View

20.

Koski L, Brouillette M, Lalonde R, Hello B, Wong E, Tsuchida A . Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment(*). HIV Med. 2011; 12(8):472-80. DOI: 10.1111/j.1468-1293.2010.00910.x. View